How CBX proteins regulate normal and leukemic blood cells

Anne P. de Groot, Gerald de Haan

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Hematopoietic stem cell (HSC) fate decisions are dictated by epigenetic landscapes. The Polycomb Repressive Complex 1 (PRC1) represses genes that induce differentiation, thereby maintaining HSC self-renewal. Depending on which chromobox (CBX) protein (CBX2, CBX4, CBX6, CBX7, or CBX8) is part of the PRC1 complex, HSC fate decisions differ. Here, we review how this occurs. We describe how CBX proteins dictate age-related changes in HSCs and stimulate oncogenic HSC fate decisions, either as canonical PRC1 members or by alternative interactions, including non-epigenetic regulation. CBX2, CBX7, and CBX8 enhance leukemia progression. To target, reprogram, and kill leukemic cells, we suggest and describe multiple therapeutic strategies to interfere with the epigenetic functions of oncogenic CBX proteins. Future studies should clarify to what extent the non-epigenetic function of cytoplasmic CBX proteins is important for normal, aged, and leukemic blood cells.
Original languageEnglish
JournalFEBS letters
Early online date2024
DOIs
Publication statusE-pub ahead of print - 2024

Keywords

  • CBX
  • HSC
  • PRC1
  • Polycomb
  • aging
  • epigenetics
  • hematopoiesis
  • leukemia
  • subcellular CBX localization

Cite this